Document is current
Any future updates will be listed below
-
Authors
Khare, Swarna
Osumili, Beatrice https://orcid.org/0000-0002-5862-9325
Debackere, Nele
Keapoletswe, Karabo
Falato, Serena
Raoul, Thomas
Coles, Briana
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 8 July 2024
Accepted: 16 September 2024
First Online: 2 November 2024
Declarations
:
: Swarna Khare, Beatrice Osumili, and Nele Debackere are employees and shareholders of Eli Lilly and Company. Briana Coles, Karabo Keapoletswe, Serena Falato, and Thomas Raoul are employees of IQVIA, which was contracted by Eli Lilly and Company to conduct the study. Briana Coles is the Vice Chair of the trial steering committee for the United Kingdom Early Detection Initiative (UK-EDI).
: The authors had permission to access and use the data from both the IQVIA LRx databases, and ethical approval was not required for secondary use of the data. This study was conducted in accordance with all relevant regulatory requirements, including, where applicable, the Declaration of Helsinki (and its amendments) and the Guidelines for Good Pharmacoepidemiology Practices (ISPE).
